Several pharmacologically active compounds present in their structure different functional groups and stereocenters so, for their synthesis, chemo-, regio-, stereoselective transformations are required. This selectivity can be achieved using biocatalysis (enzymes and microorganisms). The aim of our work is the preparation of some pharmacologically active compounds using biocatalytic methodologies which can lead to important improvements compared to traditional approaches, such as better yields and shorter synthetic pathways. Moreover, the use of biocatalysts in synthesis is a green approach. For example, in our laboratory through a regioselective transformation catalysed by an enzyme, Alcalase CLEA, we have achieved the synthesis of capecitabine (Xeloda), an antitumor with a nucleosidic scaffold. After the investigation of the activity of different enzymes and microorganisms we have obtained both the enantiomerically pure synthons for the preparation of (S)-pramipexole, a synthetic dopaminergic agonist utilized as anti-Parkinson agent, and (R)-pramipexole, which has been studied for the treatment of amyotrophic lateral sclerosis (ALS). With a similar biocatalytic approach is under development the synthesis of brivaracetam, a novel anticonvulsant drug. The crucial step of the synthesis of this molecule is the obtainment of the stereocenter bearing the propyl moiety with the proper configuration. The preliminary results are very encouraging and this biocatalytic method could be very interesting in a future application on large scale.

Biocatalytic Approach to the Synthesis of Pharmacologically Active Compounds / P. Ferraboschi, S. Ciceri, B. Guidi, S. Reza Elahi, P. Grisenti. ((Intervento presentato al 38. convegno Convegno Nazionale della Divisione di Chimica Organica della Società Chimica Italiana tenutosi a Milano nel 2018.

Biocatalytic Approach to the Synthesis of Pharmacologically Active Compounds

P. Ferraboschi;S. Ciceri
;
B. Guidi;
2018

Abstract

Several pharmacologically active compounds present in their structure different functional groups and stereocenters so, for their synthesis, chemo-, regio-, stereoselective transformations are required. This selectivity can be achieved using biocatalysis (enzymes and microorganisms). The aim of our work is the preparation of some pharmacologically active compounds using biocatalytic methodologies which can lead to important improvements compared to traditional approaches, such as better yields and shorter synthetic pathways. Moreover, the use of biocatalysts in synthesis is a green approach. For example, in our laboratory through a regioselective transformation catalysed by an enzyme, Alcalase CLEA, we have achieved the synthesis of capecitabine (Xeloda), an antitumor with a nucleosidic scaffold. After the investigation of the activity of different enzymes and microorganisms we have obtained both the enantiomerically pure synthons for the preparation of (S)-pramipexole, a synthetic dopaminergic agonist utilized as anti-Parkinson agent, and (R)-pramipexole, which has been studied for the treatment of amyotrophic lateral sclerosis (ALS). With a similar biocatalytic approach is under development the synthesis of brivaracetam, a novel anticonvulsant drug. The crucial step of the synthesis of this molecule is the obtainment of the stereocenter bearing the propyl moiety with the proper configuration. The preliminary results are very encouraging and this biocatalytic method could be very interesting in a future application on large scale.
2018
Settore BIO/10 - Biochimica
Settore CHIM/06 - Chimica Organica
Divisione di Chimica Organica-Società Chimica Italiana
Biocatalytic Approach to the Synthesis of Pharmacologically Active Compounds / P. Ferraboschi, S. Ciceri, B. Guidi, S. Reza Elahi, P. Grisenti. ((Intervento presentato al 38. convegno Convegno Nazionale della Divisione di Chimica Organica della Società Chimica Italiana tenutosi a Milano nel 2018.
Conference Object
File in questo prodotto:
File Dimensione Formato  
Atti del convegno.pdf

accesso aperto

Descrizione: Atti del convegno
Tipologia: Publisher's version/PDF
Dimensione 514.42 kB
Formato Adobe PDF
514.42 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/778401
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact